Sirolimus is a novel macrolide immunosuppressant widely used in solid organ transplantation. We have conducted three clinical trials using this compound as prophylaxis against GVHD after allogeneic stem cell transplantation. Our studies have demonstrated excellent GVHD control even when mismatched and unrelated donors were used. The morbidity and mortality associated with transplantation were reduced due to the omission or reduction in methotrexate dose. Furthermore, CMV reactivation and fungal infection rates were low. However, we have noted that sirolimus may be associated with increased rates of thrombotic microangiopathy after transplantation. Sirolimus has other uses, such as the treatment of established acute and chronic GVHD, and may be useful for treatment of post transplant lymphoproliferative disorder and perhaps as an antineoplastic agent against a wide variety of hematologic and solid neoplasms.
stem cell transplantation
Graft-vs-host disease (GVHD) remains the most significant cause of morbidity and mortality after allogeneic stem cell transplantation. Despite this, the combination of a calcineurin inhibitor with methotrexate remains the standard of care 15 years after Storb et al 1 initially demonstrated its effectiveness. Numerous attempts to improve upon this regimen have been largely unsuccessful. In order to address this problem, we began clinical trials with the novel immunosuppressant, sirolimus, for GVHD prophylaxis after allogeneic stem cell transplantation in 2000. At that time, the compound had already become a commonly used agent in renal and hepatic transplantation. In this review, we describe our experience with this compound and discuss the potential future for the broader use of sirolimus in stem cell transplantation.
Sirolimus: background and mechanism of action Sirolimus (Rapamune s , Wyeth) is a naturally occurring compound originally isolated from a soil saprophyte (Streptomyces hygroscopicus) found uniquely on Easter Island (Rapa Nui). In addition to its immunosuppressive properties, sirolimus has antifungal, antiviral and antineoplastic properties.
Although structurally similar to other calcineurin inhibitors ( Figure 1 ), sirolimus binds uniquely to FK binding protein 12 (FKBP12) and then complexes with mammalian target of rapamycin (mTOR). Sirolimus does not interact with calcineurin or its downstream effectors. As shown in Figure 2 , the sirolimus-FKBP12-mTOR complex inhibits IL-2-mediated proliferation signaling via several distinct biochemical pathways, with a reduction in DNA transcription, DNA translation, protein synthesis and cell cycling, ultimately leading to T-cell immunosuppression. Upstream pathways that interact with mTOR include the PTEN/PI3 kinase/Akt pathway and the Janus kinase pathway, which is important in mediating IL-2-driven signaling from the T-cell receptor. 2 Although the mechanisms are less clear, sirolimus appears to exert some of its immunosuppressive properties via inhibition of dendritic cell activity through a reduction in antigen uptake, 3,4 cellular maturation, 5 intracellular signaling 6 and apoptosis induction in dendritic cells. 7, 8 Sirolimus has been used widely in renal transplantation, liver transplantation and in transplantation of other solid organs. In renal transplantation, several randomized trials have demonstrated that the addition of sirolimus to an established immunosuppressive regimen is associated with improved allograft survival 9,10 and long-term renal function 11 after transplantation. Although sirolimus has not been tested in a randomized fashion after liver transplantation, there is ample evidence to suggest that its introduction to facilitate early calcineurin minimization has lead to a reduction in adverse renal outcomes without increasing the graft rejection rate after transplantation. [12] [13] [14] [15] The use of combination immunosuppression with sirolimus in stem cell transplantation is attractive, since the drug has nonoverlapping toxicities with the calcineurin agents and a different mechanism of action (Table 1) . When used as part of combination immunosuppressive therapy, the combination of sirolimus with tacrolimus has been shown to be the most efficacious. In vitro studies have suggested that this combination is more effective than sirolimus and cyclosporine in reduction of memory T-cell production, apoptosis induction and cytokine production. 16 When tested in a comparative fashion after renal transplantation, early results suggested fewer episodes of acute rejection and better preservation of renal function when sirolimus and tacrolimus were used in combination in comparison with sirolimus and cyclosporine. 17, 18 Practical aspects of sirolimus use in allogeneic transplantation
Sirolimus is a relatively simple compound to use. Although it exists only as an oral formulation (liquid and tablet), due to its extremely long half-life (60-72 h), missed doses due to transplant-related nausea and mucositis are rarely of important clinical consequence. Drug levels must be measured by HPLC, as ELISA-based assays generally will measure both sirolimus and its metabolites, which are variably generated and variably immunosuppressive. Again, due to the long half-life of sirolimus, serum levels can be measured throughout the day, but trough measurements are preferred. Sirolimus has several known drug interactions, which largely resemble those of tacrolimus; however, the concomitant use of voriconazole with sirolimus is difficult, as drug absorption (as low as 10% at baseline) can rise as much as 100-fold due to inhibition of sirolimus metabolism by the cytochrome P450 enzyme, CYP 3A4, in the bowel wall (Tables 1 and 2) .
Common side effects of sirolimus include the development of hyperlipidemia (both hypercholesterolemia and hypertriglyceridemia) with prolonged use, particularly when combined with a calcineurin inhibitor (cyclosporine more than tacrolimus). In addition, mild reversible cytopenias are common with prolonged exposure. Other well-described side effects of chronic sirolimus use in the solid-organ transplant setting include lower extremity edema, arthralgias, oral aphthous ulcers and interstitial pneumonitis. 19 
Treatment of established GVHD
In the only published report on therapy of established steroid-refractory acute GVHD, Benito et al described their experience treating 21 patients with sirolimus. Most patients were treated with 4-5 mg/m 2 /day and some were given an oral loading of 15 mg/m 2 . Although the drug was active in this patient population (overall response rate 57%), the drug proved to be too toxic at the doses used, as five patients developed thrombotic microangiopathy and many others had reversible cytopenias. 20 The efficacy of this agent as therapy for chronic GVHD in combination with calcineurin inhibitors has been described a 56% overall response rate when sirolimus was given with either tacrolimus or cyclosporine in patients with established chronic GVHD, while Couriel et al 22 described a 68% response rate to the combination of sirolimus and tacrolimus in steroid-refractory chronic GVHD.
GVHD prophylaxis
Since 2000, we have conducted three clinical trials evaluating the role of sirolimus as primary prophylaxis against GVHD. In all three studies, sirolimus was given as a fixed oral loading dose of 12 mg, 3 days prior to stem cell transplantation and then 4 mg by mouth, per day, in order to maintain a serum trough level of 3-12 ng/ml.
In the HLA-matched, unrelated donor and single antigen-mismatched, related donor setting, over 65 patients have undergone allogeneic bone marrow transplantation at the Dana-Farber Cancer Institute using the combination of sirolimus, tacrolimus and abbreviated methotrexate (5 mg/m 2 day þ 1, þ 3, þ 6, þ 11) as GVHD prophylaxis. Updated results on the first 41 patients and survival data on the entire cohort are presented in Table 3 (Trial 1). 23 Presumably due to a reduction in methotrexate dose, rapid neutrophil and platelet engraftment was noted. The incidence of Grades II-IV and III-IV acute GVHD was 26 and 13%, respectively. Overall, the combination was safe with the occurrence of only eight cases of venoocclusive disease of the liver (12%) and five cases of interstitial pneumonitis/idiopathic pneumonia syndrome (8%). For the entire 65 patient cohort, chronic GVHD has been noted in 48% of patients surviving at least 100 days. The relapse rate in this high-risk, unselected population was only 22%. Overall survival for the entire high-risk population at 1 year is 56% and at 2 years, the corresponding figure is 50%. When stratified by risk, 61% of low-risk patients remain alive at 2 years, while 43% of high-risk patients remain alive (Figure 3) .
In the HLA-matched, related donor setting, 50 patients have undergone peripheral blood stem cell transplantation at the Dana-Farber Cancer Institute using sirolimus and tacrolimus without methotrexate as GVHD prophylaxis. Data on the first 38 patients surpassing the 100-day mark are presented in Table 3 (Trial 2). Since sirolimus, tacrolimus and methotrexate adequately controlled the rate of GVHD in unrelated donor and mismatched setting, the hypothesis tested in this trial was that the omission of methotrexate would not increase the rate of GVHD and would reduce transplant-related toxicity. The median times to neutrophil and platelet engraftment were 14 days (range 9-17 days) and 13 days (range 10-47 days), respectively. This is several days shorter than the median times reported in the literature and is reflective of the omission of methotrexate in this study. The rates of Grades II-IV and III-IV acute GVHD were 15 and 4% at 100 days. Transplant-related toxicity has been limited: five patients developed severe veno-occlusive disease of the liver (10%) and one patient (2%) developed idiopathic pneumonia syndrome. CMV reactivation rates were low and no patient developed an invasive fungal infection during hospitalization. Mucositis, when assessed prospectively, was moderate and the majority of patients required no parenteral nutritional support. Of the 50 patients, 48 survived to first hospital discharge, which occurred at a median of 19 days from the infusion of stem cells. Transplant-related mortality at 100 days was only 6%. With a median follow-up of over 1 year, overall survival at 1 year is 72% 24 ( Figure 3 ). 
Sirolimus in allogeneic transplantation C Cutler and JH Antin
Using nonmyeloablative conditioning and the combination of sirolimus, tacrolimus and low-dose methotrexate (15 mg/m 2 total), 39 patients underwent transplantation from HLA-matched related and unrelated bone marrow transplantation (Table 3 , Trial 3). Peritransplant toxicity was expectedly minimal, however, only 5% of patients developed any degree of acute GVHD. Although follow-up remains short, the 1 year overall survival estimate is 74%. 25 Transplantation with sirolimus-based immunosuppression using alternative donors (haploidentical, single HLAantigen mismatched related and matched unrelated) has been described as well. Using sirolimus, tacrolimus, methotrexate and anti-thymocyte globulin (for haploidentical donors), Claxton et al 26 demonstrated stable engraftment but a 66% rate of acute GVHD.
Thrombotic microangiopathy: a potential complication of sirolimus use
A syndrome of thrombotic microangiopathy, comprised of renal dysfunction, microangiopathic hemolysis and thrombocytopenia, occurred in five patients (10%) in our matched, related donor study of sirolimus and tacrolimus. In addition, we have noted the occurrence of thrombotic microangiopathy in a number of patients receiving sirolimus as therapy for established acute GVHD at the Dana-Farber Cancer Institute.
The association of thrombotic microangiopathy with cyclosporine or tacrolimus after allogeneic stem cell transplantation and solid-organ transplantation is well known. 27, 28 Recently, the combination of sirolimus and calcineurin inhibitors has been associated with the syndrome. 29, 30 Sirolimus may promote thrombotic microangiopathy via direct endothelial damage or may potentiate the effects of calcineurin inhibitors; 31, 32 however, there is only one case report of de novo thrombotic microangiopathy related to sirolimus monotherapy. 33 The mechanism of sirolimus-induced microangiopathy may be molecular mimicry between sirolimus and tacrolimus; however, conversion from tacrolimus to sirolimus as therapy for thrombotic microangiopathy has been reported without apparent untoward effects. [34] [35] [36] In all cases reviewed at the Dana-Farber, thrombotic microangiopathy resolved spontaneously when tacrolimus was discontinued and sirolimus was held, in the event of supratherapeutic levels. No longterm renal complications have been noted, to date. We strongly recommend that when used in combination with a calcineurin agent, levels of both sirolimus and the calcineurin inhibitor are monitored frequently.
Future applications of sirolimus and mTOR inhibitors: harnessing antiviral and antineoplastic properties in transplantation
Sirolimus has been used successfully in conjunction with Rituximab as therapy for post transplant lymphoproliferative disorder in three cases. 37 Supporting the reported favorable clinical results is the fact that in vitro, everolimus (Certican s , Novartis), a sirolimus analog, as well as sirolimus are capable of suppressing the growth of EBVtransformed lymphocytes. 38, 39 Sirolimus may be effective in preventing the growth of lymphocytes infected with other members of the herpesvirus family as well. The incidence of reactivation of CMV in our clinical studies was very low (o10%). In fact, in our matched, related donor GVHD prophylaxis trial, there was only one case of CMV reactivation among the first 18 donor-recipient seropositive pairs. It is unclear whether sirolimus or the absence of acute GVHD and high-dose steroid use was responsible for the low rate of viral reactivation. However, it is known that CMV specifically upregulates the PI3 kinase/Akt pathway during replication and therefore, inhibition of this pathway by sirolimus may be directly responsible for reduced viral reactivation. 40, 41 Low rates of CMV reactivation have not limited to stem cell transplantation, as reports of less frequent CMV reactivation exist for both renal 42 and hepatic transplantation. 43 Similarly, the rates of reactivation of the BK polyoma virus have been noted to be low when sirolimus is used as immunosppression. 42 The broader applicability of sirolimus and the other mTOR inhibitors as antineoplastic agents has recently been explored. To date, both preclinical and phase I/II clinical trials have been conducted in renal cell carcinoma, 44 breast cancer 45, 46 and other solid tumors. [47] [48] [49] [50] [51] It is interesting to note that the side effect profile of these compounds when used as therapy for solid tumors is strikingly different than the toxicities seen in transplantation. In the randomized, phase II study in renal cancer, the most common toxicities included maculopapular rash (76%), mucositis (70%), asthenia (50%) and nausea (43%). 44 In addition, the activity of mTOR inhibitors has been tested in hematologic neoplasms that are currently treated by allogeneic stem cell transplantation. 52 Brown et al 53 demonstrated suppression of lymphoblastic leukemia growth both in vitro and in a transgenic mouse model modulated by sirolimus' inhibition of the p70 S6 kinase pathway. Similarly, Decker et al 54 have demonstrated similar findings using CLL as a model. mTOR inhibitors are also being tested as a rationale target in CML, since the BCR-ABL kinase promotes cell cycling through the p70 S6 kinase and the PI3 kinase pathway. 55, 56 Other future applications of sirolimus and other mTOR inhibitors are displayed in Table 4 .
Sirolimus, when used as part of combination immunosuppression after allogeneic stem cell transplantation is safe Table 4 Future applications of sirolimus and other mTOR inhibitors and highly effective in reducing the incidence and severity of acute GVHD. Fears that more efficient GVHD prophylaxis may lead to less potent GVL responses may be unfounded if the GVHD prophylaxis agent itself has direct antitumor activity. If in addition, this GVHD prophylaxis agent were capable of controlling viral infections after transplantation, then this agent would certainly become an important part of all GVHD prophylaxis regimens. Randomized trials to confirm these preliminary findings and hypotheses are in development at this time.
